The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective cytotoxic activity in neuroblastoma
Our recent study revealed that the chemotherapeutic CX-5461 primarily binds and inhibits TOP2B, exhibiting selective cytotoxicity in neuroblastoma cells, which overexpress TOP2B. As such, pharmacological targeting of TOP2B raises safety concerns due to off-target drug interactions with this gene.
